Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

In this issue of The Lancet Diabetes & Endocrinology, Michelle M Chen and colleagues1 report their findings on trends in the incidence of thyroid cancer in the USA from 1975 to 2019. The authors show ...

In the early, busy weeks of President Trump's administration, a new survey shows how Americans would define a healthy America ...

President Trump took to Truth Social this week to express his shock over rising rates of autism in the US. Doctors have ...